Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Molipaxin

Molipaxin
In stock
25mg · 50mg · 100mg
from 25,22 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
37,61 £31,34 £
1,04 £ per tablet

In brief

  • In our pharmacy, you can buy Molipaxin without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
  • Molipaxin (trazodone) is used for major depressive disorder and is commonly used off‑label for insomnia and sleep disturbances; it is a serotonin antagonist and reuptake inhibitor (SARI) that blocks certain 5‑HT receptors and inhibits serotonin reuptake, with additional antihistaminic and alpha‑adrenergic blocking effects.
  • The usual dosage for depression starts at around 150 mg per day in divided doses, with doses up to 300 mg/day (and up to 600 mg/day in hospital settings); for insomnia, off‑label bedtime doses are typically 25–100 mg, usually not exceeding 150 mg.
  • The form of administration is oral: capsules (50 mg, 100 mg), tablets (150 mg) and oral solution.
  • The effect for sleep typically begins within 25–60 minutes; antidepressant benefits may begin in 1–2 weeks with full effect commonly seen in 4–6 weeks.
  • The duration of action for sedative effects is generally about 6–8 hours for immediate‑release formulations; antidepressant effects are maintained with regular daily dosing.
  • Do not consume alcohol with Molipaxin — alcohol increases drowsiness and the risk of respiratory depression, severe sedation and hypotension.
  • The most common side effect is drowsiness/sedation.
  • Would you like to try Molipaxin without a prescription?

Basic Molipaxin information

  • INN (international nonproprietary name): Trazodone
  • Brand names available in the United Kingdom: Molipaxin; generic trazodone.
  • ATC code: N06AX05
  • Forms and dosages: Capsules 50 mg, 100 mg; tablets 150 mg; oral solution 50 mg/5 ml.
  • Manufacturers in the United Kingdom: Angelini Pharma (originator) and generic manufacturers such as Teva, Sandoz, Mylan and others.
  • Registration status in the United Kingdom: Marketed in the United Kingdom as Molipaxin and as generic trazodone; prescription-only.
  • OTC / Rx classification: Prescription-only medicine (POM); never available over the counter.

Critical warnings and restrictions

Patient safety must come first when considering Molipaxin (trazodone).

Absolute contraindications include known hypersensitivity, recent or concurrent monoamine oxidase inhibitor (MAOI) use within 14 days, and use in the acute recovery phase following myocardial infarction.

Relative cautions include cardiac disease, history of seizures, significant hepatic or renal impairment and any current risk of suicidality.

Elderly patients are at higher risk of sedation, orthostatic hypotension and falls and should start on lower doses with close monitoring.

Pregnancy and breastfeeding require specialist review to balance maternal mental health against neonatal risk and to document shared decision-making.

For safety-critical workplaces, including driving and operation of heavy machinery, UK fitness‑to‑work rules require workplace risk assessment plus clinician or pharmacist advice before resuming duties.

High‑risk groups

Elderly people should begin at lower doses and be monitored for daytime drowsiness and blood pressure changes.

Pregnant or breastfeeding people should discuss options with a specialist; trazodone requires individual risk/benefit assessment.

People with chronic illness such as heart disease, hepatic or renal impairment, and those with a seizure history need dose adjustments and closer review.

Interaction with activities

Trazodone commonly causes sedation and impaired concentration, which can affect driving and workplace safety.

Employers and clinicians should perform a workplace risk assessment where duties are safety critical.

Q&A — “Can I drive after taking it in the UK?”

No firm guarantee can be given that you will be safe to drive after taking trazodone.

If you feel drowsy, dizzy or have impaired concentration do not drive.

Inform DVLA or occupational health only if you have a long‑term impairment that could affect driving safety and discuss timing with your prescriber and pharmacist.

  • Immediate red‑flag symptoms: severe dizziness, fainting, chest pain, rapid heartbeat, suicidal thoughts.
  • Monitoring checklist: baseline and periodic blood pressure, ECG if cardiac history, routine mood and suicidality assessments, falls‑prevention review at home (non‑slip rugs, raised toilet seat, mobility aids).

Usage basics

INN, brand names available in the UK

Trazodone is the International Nonproprietary Name (INN) typically used in UK practice.

It is often dispensed simply as trazodone, or under the UK brand name Molipaxin.

Legal classification

Trazodone is a prescription‑only medicine (POM) across the UK and is never available over the counter.

Dispensing occurs on NHS prescriptions, private prescriptions or NHS e‑prescriptions with pharmacist counselling at point of supply.

Check the MHRA and the product SPC for brand‑specific details and marketing authorisation; some brands and strengths vary by supplier.

  1. INN: International Nonproprietary Name.
  2. POM: Prescription‑Only Medicine.
  3. SPC: Summary of Product Characteristics.
  4. MHRA: Medicines and Healthcare products Regulatory Agency.

Dosing guide

Standard regimens

Trazodone dosing varies by indication.

For major depressive disorder a common starting total dose is 150 mg per day in divided doses with upward titration.

In the UK the usual maximum is 300 mg per day, with up to 600 mg per day used in hospital settings.

For insomnia the off‑label single evening doses range from 25 mg to 100 mg, and sleep dosing usually does not exceed 150 mg.

Children are not approved for use.

Adjustments for comorbidities

Elderly patients should start at lower doses and increase slowly while monitoring for sedation and hypotension.

Hepatic or renal impairment often requires dose reduction and specialist review; specific adjustments depend on clinical judgement and SPC guidance.

Patients with seizure history or significant cardiac disease should be reviewed by a specialist before dose escalation.

  • Titration steps: start low, review after 1–2 weeks, assess effect by 4–6 weeks and adjust as clinically indicated.
  • Monitoring checklist: blood pressure, falls risk, mood and suicidality assessments, sexual side‑effect enquiries.

Q&A — “What if I miss a dose?”

Take the missed dose as soon as you remember unless the next scheduled dose is due.

Do not double the next dose to make up.

If you are unsure, contact your pharmacist or prescriber and record missed doses for review.

Interaction chart

Food and drinks

Alcohol has additive sedative effects with trazodone and impairs psychomotor function.

Avoid alcohol when initiating therapy or while doses are being adjusted.

Caffeine in tea or coffee can mask sedative effects but does not prevent impairment; discuss habits with your clinician.

Common drug conflicts

The most serious contraindicated interaction is with MAO inhibitors; avoid MAOI use within 14 days of trazodone.

Trazodone is metabolised via hepatic CYP enzymes, notably CYP3A4.

Strong CYP3A4 inhibitors increase trazodone plasma levels and require dose adjustment and close monitoring.

Concomitant serotonergic agents, St John’s wort and certain opioids increase the risk of serotonin syndrome.

QT‑prolonging drugs and other cardiac medications may necessitate ECG monitoring.

Drug/class Interaction type Practical advice
MAO inhibitors Contraindicated; risk of serotonin syndrome Do not co‑prescribe; avoid within 14 days of MAOI use
Strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin) Increased trazodone levels Consider dose reduction and enhanced monitoring
SSRIs, SNRIs, St John’s wort Serotonergic additive effect Monitor for serotonin syndrome; review combination necessity
QT‑prolonging drugs (e.g. certain antiarrhythmics) Increased arrhythmia risk ECG monitoring advised if clinically indicated
Alcohol and sedative antihistamines Additive sedation Avoid during initiation and dose changes
  • Dietary cautions: avoid alcohol while starting or changing dose; moderate caffeine intake and report herbal supplement use.
  • What to bring to your pharmacy or GP: a full current medication list including OTC and herbal remedies, recent alcohol use pattern and any allergy history.

Legal status and availability in the UK

In our online pharmacy, Molipaxin is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Trazodone acts as a serotonin antagonist and reuptake inhibitor with 5‑HT2 receptor antagonism and alpha‑adrenergic blocking properties.

These combined actions contribute to antidepressant effects and the commonly observed sedative properties that are useful for insomnia at lower doses.

Clinical terms

ATC code N06AX05 places trazodone in the “other antidepressants” group.

Hepatic CYP metabolism (notably CYP3A4) affects interactions and dosing considerations in hepatic impairment.

  1. INN: International Nonproprietary Name.
  2. ATC code: N06AX05 — antidepressant class code.
  3. CYP3A4: Key hepatic enzyme involved in trazodone metabolism.
  4. SPC: Summary of Product Characteristics for brand details.
Mechanism Clinical effect Monitoring need
Serotonin reuptake inhibition + 5‑HT2 antagonism Antidepressant effect; improved sleep Mood assessment, suicidality monitoring
Alpha‑adrenergic blockade Orthostatic hypotension; sedation BP checks, falls prevention

Indications and off‑label uses

MHRA‑approved uses

In the UK, trazodone is licensed for depressive illness (particularly where sedation is required) and for anxiety.

Off‑label practices in NHS and private care

Common off‑label uses in UK practice include low‑dose evening use for insomnia and adjunctive treatment for anxiety‑related sleep disturbance.

Private psychiatrists may consider trazodone for refractory depression when SSRIs have been insufficient, often using it alongside management of insomnia.

Paediatric use is not approved and should be avoided unless directed by a specialist.

  • Licensed uses: depressive illness and anxiety.
  • Off‑label uses: Low‑dose insomnia treatment, adjunctive sleep management, anxiety‑related sleep disturbance.
  • Off‑label checklist for clinicians: review evidence, obtain informed consent, document rationale, set monitoring plan.

Alternatives matrix

NHS prescribing alternatives

Drug (INN) Typical indication Sedation profile Anticholinergic burden Sexual side‑effects Key monitoring
Mirtazapine Depression, insomnia High (sedating) Low Low Weight, lipids, mood
Amitriptyline Depression, neuropathic pain, insomnia High High Moderate ECG in cardiac risk, anticholinergic effects
Sertraline Depression, anxiety Low Low Moderate Monitor nausea, sexual function
Paroxetine Depression, anxiety Low Low Moderate to high Withdrawal risk on stopping

Pros and cons checklist

  • Consider trazodone when sleep improvement is needed alongside antidepressant effect.
  • Mirtazapine is useful if sedation is desired but may increase appetite and weight.
  • Amitriptyline carries greater anticholinergic and cardiac risks and requires more monitoring in older patients.
  • SSRIs such as sertraline are less sedating and often preferred first‑line for depression without insomnia.
  • Substitution steps: document rationale, plan stop/start and tapering, monitor for withdrawal or recurrence of symptoms.

Common questions

Will it make me sleepy all day?

Initial sedation is common, especially when starting or after dose increases.

Timing the dose at night and gradual titration often reduces daytime sleepiness.

How long until it works?

Some benefit may occur within 1–2 weeks with fuller antidepressant effect by 4–6 weeks.

Can I drink alcohol?

Avoid alcohol when starting trazodone or when doses change because of additive sedation and impaired judgement.

Is it addictive?

Trazodone is not classically addictive, but abrupt stopping can cause withdrawal‑like effects; taper gradually when discontinuing.

Report any worsening mood or suicidal thoughts immediately to NHS 111, your GP or emergency services.

Registration and regulation

MHRA approval process

The MHRA oversees licensing and post‑marketing safety in the UK.

Individual brands hold UK marketing authorisations and the SPC should be consulted for brand‑specific dosing and contraindications.

Check the SPC for up‑to‑date safety information.

NHS prescribing framework

GPs prescribe according to NICE guidance and local formularies; specialists manage complex cases.

The Yellow Card scheme is used to report suspected adverse drug reactions; patients and clinicians are encouraged to report serious or unexpected events.

  • SPC checks for dosing and contraindications.
  • Yellow Card reporting for serious adverse events such as serotonin syndrome or cardiac events.
  1. MHRA: UK medicines regulator.
  2. SPC: product Summary of Product Characteristics.
  3. Yellow Card: adverse reaction reporting scheme.

Storage and handling

UK household storage

Store trazodone at room temperature, ideally between 15°C and 30°C, protected from moisture and light.

Because UK homes can be humid, keep tablets in a dry cupboard away from bathrooms and kitchen steam.

Keep medicines in original packaging with the leaflet to preserve expiry and batch information.

Guidance from NHS and pharmacists

For liquid formulations ensure bottles are tightly capped and follow any manufacturer guidance about expiry after opening.

Keep all medicines out of reach of children and pets and return unused medication to a pharmacy for safe disposal.

  • Safe storage checklist: correct temperature range, dry location, child safety, check expiry dates.

Guidelines for proper use

UK pharmacist counselling style

Pharmacists should confirm the indication and dosing schedule and advise about sedation and driving risk.

Review concurrent medicines including OTC and herbal remedies and discuss simple side‑effect measures such as sipping water for dry mouth or standing slowly for dizziness.

Document patient understanding and consent on the clinical record where possible.

NHS patient safety advice

Arrange follow‑ups at 1–2 weeks and 4–6 weeks with baseline blood pressure and consideration of ECG if cardiac risk exists.

Maintain suicide risk monitoring for younger adults and those with prior ideation.

When discontinuing, emphasise gradual tapering to reduce withdrawal symptoms.

  1. POM: prescription requirement reminder.
  2. ATC code: N06AX05.
  3. SPC: check for brand specifics.
  • First‑dispense counselling checklist: what to expect, potential red flags, monitoring schedule, pharmacist/GP contact numbers for urgent advice.

Delivery across the United Kingdom

City Region Delivery time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Manchester Greater Manchester 9–21 days
Glasgow Scotland 9–21 days
Leeds West Yorkshire 9–21 days
Liverpool Merseyside 9–21 days
Bristol South West England 9–21 days
Edinburgh Scotland 9–21 days
Sheffield South Yorkshire 9–21 days
Newcastle Upon Tyne North East England 9–21 days
Belfast Northern Ireland 9–21 days
Cardiff Wales 9–21 days
Plymouth South West England 9–21 days

Related products